L
Linda Mol
Publications - 53
Citations - 3953
Linda Mol is an academic researcher. The author has contributed to research in topics: Colorectal cancer & Bevacizumab. The author has an hindex of 21, co-authored 45 publications receiving 3525 citations.
Papers
More filters
Journal ArticleDOI
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol,Miriam Koopman,Annemieke Cats,C.J. Rodenburg,Geert Jan Creemers,Jolanda G Schrama,Frans L. G. Erdkamp,A. Vos,Cees J van Groeningen,Harm Sinnige,Dirk J. Richel,Emile E. Voest,Jeroen R. Dijkstra,Marianne E. Vink-Börger,Ninja Antonini,Linda Mol,Johan H. J. M. van Krieken,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression-free survival and inferior quality of life.
Journal ArticleDOI
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Miriam Koopman,Ninja Antonini,Joep Douma,Jaap Wals,Aafke H. Honkoop,Frans L. G. Erdkamp,Robert S. de Jong,C.J. Rodenburg,Gerard Vreugdenhil,Olaf J. L. Loosveld,Aart van Bochove,Harm Sinnige,Geert-Jan Creemers,Margot E T Tesselaar,Peter H. Th J. Slee,Marjon J. B. P. Werter,Linda Mol,Otilia Dalesio,Cornelis J. A. Punt +18 more
TL;DR: Combination treatment does not significantly improve overall survival compared with the sequential use of cytotoxic drugs in advanced colorectal cancer, and sequential treatment remains a valid option for patients with advanced coloresceptic cancer.
Journal ArticleDOI
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H.J. Simkens,Harm van Tinteren,Anne May,Albert J. ten Tije,Geert-Jan Creemers,Olaf Loosveld,Felix E de Jongh,Frans L. G. Erdkamp,Zoran Erjavec,Adelheid M. E. van der Torren,Jolien Tol,Hans J Braun,Peter Nieboer,Jacobus J.M. van der Hoeven,Janny G. Haasjes,Rob L. H. Jansen,Jaap Wals,Annemieke Cats,Veerle A. Derleyn,Aafk E. H. Honkoop,Linda Mol,Cornelis J. A. Punt,Miriam Koopman +22 more
TL;DR: Maintenance treatment with capecitabine plus bevacizumab after six cycles of CAPOX-B in patients with metastatic colorectal cancer is effective and does not compromise quality of life.
Journal ArticleDOI
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Jolien Tol,Miriam Koopman,C.J. Rodenburg,Annemieke Cats,Geert Jan Creemers,J. G. Schrama,Frans L. G. Erdkamp,A. Vos,Linda Mol,Ninja Antonini,C.J.A. Punt +10 more
TL;DR: The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible.
Journal ArticleDOI
Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial
Charlotte E. L. Klaver,Daniel D Wisselink,Cornelis J. A. Punt,Petur Snaebjornsson,Johannes Crezee,Arend G. J. Aalbers,Alexandra Brandt,A.J.A. Bremers,Jacobus W. A. Burger,Hans F. J. Fabry,Floris Ferenschild,Sebastiaan Festen,Wilhelmina M U van Grevenstein,Patrick H. J. Hemmer,Ignace H. J. T. de Hingh,Niels F. M. Kok,Gijsbert D. Musters,Lotte Schoonderwoerd,Jurriaan B. Tuynman,Anthony W. H. van de Ven,Henderik L van Westreenen,Marinus J. Wiezer,David D. E. Zimmerman,Annette A van Zweeden,Marcel G. W. Dijkgraaf,Pieter J. Tanis,Caroline S. Andeweg,Vivian P. Bastiaenen,Willem A. Bemelman,Jarmila D. W. van der Bilt,Johanne Bloemen,Frank C. den Boer,Djamila Boerma,Daan ten Bokkel Huinink,Walter J.A. Brokelman,Huib A. Cense,Esther C. J. Consten,Geert-Jan Creemers,Rogier M P H Crolla,J. W. T. Dekker,Jennifer Demelinne,Marc J. van Det,Karin K. van Diepen,Marjolein Diepeveen,Eino B. van Duyn,Esther D. van den Ende,Pauline Evers,Anna A. W. van Geloven,Erwin van der Harst,Jeroen Heemskerk,Joost T. Heikens,Daniel A. Hess,Bas Inberg,Jan Jansen,Frank W.H. Kloppenberg,Thomas J.M. Kootstra,R.T.J. Kortekaas,Maartje Los,Eva V. E. Madsen,H.C.J. van der Mijle,Linda Mol,P.A. Neijenhuis,Simon W. Nienhuijs,Loes van den Nieuwenhof,Koen C.M.J. Peeters,Sebastiaan W. Polle,Jolien Pon,Pieter Poortman,Sandra A Radema,Bert van Ramshorst,Philip R. de Reuver,Koen P. Rovers,Roderick F. Schmitz,Nina R. Sluiter,Dirkje W. Sommeijer,D. J. A. Sonneveld,T.C. van Sprundel,Sanne C. Veltkamp,Maarten Vermaas,Victor J. Verwaal,Emma C. E. Wassenaar,Johannes A. Wegdam,Johannes H. W. de Wilt,M. Westerterp,Fennie Wit,Arjen J. Witkamp,Karlijn van Woensdregt,Edwin S. van der Zaag,Mandy Zournas +88 more
TL;DR: In patients with T4 or perforated colon cancer, treatment with adjuvant HIPEC with oxaliplatin did not improve peritoneal metastasis-free survival at 18 months, and there was no difference in peritonealan metastasis free-survival in the intention-to-treat population.